#5-09E. Shifting Paradigms in Adult Uveitis: From Steroids to Biologics (JAMA, 2025)

Are you struggling with managing corticosteroid-induced complications like cataracts and glaucoma in your uveitis patients? Today's episode covers "Uveitis in Adults: A Review," a comprehensive article detailing the epidemiology, pathophysiology, diagnosis, and management of adult uveitis. The paper highlights that uveitis predominantly affects adults aged 20 to 50 and emphasizes the necessity of accurate classification into infectious or non-infectious types to guide appropriate therapies and prevent severe visual impairment. The most critical clinical takeaway is the establishment of a clear treatment algorithm that positions disease-modifying antirheumatic drugs (DMARDs) as the first-line therapy for non-infectious posterior uveitis, with biologics like adalimumab recommended as second-line for refractory cases. However, when critically appraising this review, it is important to note the lack of a systematic quality assessment of the included evidence and the limited long-term data on the effectiveness of these newer biologic treatments. For practicing clinicians, this review is highly relevant as it offers actionable strategies to minimize steroid reliance, thereby reducing adverse effects while optimizing visual outcomes in daily practice.

Citation: Maghsoudlou P, Dick AD. Uveitis in Adults: A Review. Journal of the American Medical Association. 2025. DOI: 10.1001/jama.2025.4358

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.